PLATFORM Q ARTIFICIAL INTELLIGENCE LIMITED

PlatformQ Artificial Intelligence Limited is a specialized AI company that emerged in the early 2020s, focusing on precision medicine and multimodal data integration.

Reviewed by 7wData
Share Email

On this page

Profile

Develops AI systems that analyze medical data to personalize cancer treatments and accelerate drug discovery.

PlatformQ Artificial Intelligence Limited is a specialized AI company that emerged in the early 2020s, focusing on precision medicine and multimodal data integration. While specific founding details and headquarters location remain undisclosed in public filings, the company has positioned itself at the intersection of healthcare diagnostics and AI-driven data applications. Its technology platform aggregates clinical, genomic, and imaging data to support personalized treatment decisions.

Recent financial disclosures indicate rapid growth, with preliminary 2025 revenue reaching approximately $1.27 billion (83% year-over-year growth) across two main business lines: diagnostics ($955 million revenue) and data/applications ($316 million revenue). The diagnostics segment saw particularly strong oncology volume growth (26%) and hereditary testing expansion (29%), while data licensing revenue grew 38% annually. This dual revenue model—combining diagnostic testing with data monetization—has attracted attention from both healthcare providers and pharmaceutical partners.

The company's AI operating system aims to create feedback loops where patient data continuously improves treatment algorithms. However, its heavy reliance on oncology testing (50% of semiconductor test revenue by 2025) creates both specialization benefits and market concentration risks. Recent SEC filings highlight ongoing investments in robotics and autonomous systems, suggesting expansion beyond core diagnostic applications.

Track PLATFORM Q ARTIFICIAL INTELLIGENCE LIMITED and 240+ vendors.

48k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Oncology clinics and hospital networks ordering genomic tests
  • Pharmaceutical companies licensing de-identified patient data for R&D
  • Academic medical centers using AI tools for clinical research
  • Health systems implementing precision medicine programs
  • Biotech firms partnering on therapeutic target discovery

Strengths and what to watch

Strengths

  • Demonstrated 83% revenue growth in 2025 with $1.27B total revenue, showing scalable adoption
  • Owns one of the largest multimodal healthcare datasets (clinical, genomic, imaging) with demonstrated 38% annual growth in data licensing
  • Proprietary AI operating system creates network effects as more patient data improves algorithm accuracy

Watch for

  • Revenue concentration in oncology diagnostics (50% of semiconductor test revenue) creates vulnerability to reimbursement changes
  • SEC filings note material uncertainty in preliminary 2025 financials pending audit completion
  • Increasing competition from large tech firms entering healthcare AI, potentially commoditizing data analytics

Key Information

Founded
2006
Headquarters
Needham, Massachusets

Frequently Asked Questions

What does PlatformQ Artificial Intelligence Limited do?

PlatformQ Artificial Intelligence Limited develops AI systems that analyze medical data to personalize cancer treatments and accelerate drug discovery. Its technology integrates clinical, genomic, and imaging data to support precision medicine and improve treatment algorithms.

How does PlatformQ use AI in healthcare?

PlatformQ uses AI to analyze multimodal healthcare data, including clinical, genomic, and imaging information. This enables personalized cancer treatments, accelerates drug discovery, and creates feedback loops where patient data continuously improves AI-driven treatment algorithms.

What is PlatformQ’s revenue model?

PlatformQ operates a dual revenue model combining diagnostic testing and data monetization. Its diagnostics segment generates revenue from oncology testing, while its data/applications segment licenses de-identified patient data to pharmaceutical companies and other partners for R&D purposes.

Who are PlatformQ’s main customers?

PlatformQ’s main customers include oncology clinics, hospital networks, pharmaceutical companies, academic medical centers, and biotech firms. These clients use its AI tools for precision medicine, genomic testing, therapeutic target discovery, and clinical research.

What are the risks for PlatformQ’s business?

PlatformQ faces risks such as revenue concentration in oncology diagnostics, potential reimbursement changes, and increasing competition from large tech firms entering healthcare AI. Its reliance on oncology testing creates market concentration risks despite its specialization benefits.

How fast is PlatformQ growing?

PlatformQ achieved 83% year-over-year revenue growth in 2025, reaching $1.27 billion. Its diagnostics segment grew by 26% in oncology volume, while data licensing revenue increased by 38%, demonstrating rapid adoption and scalability in healthcare AI applications.

Sources

  1. www.sec.gov — 2025 preliminary financial results showing $1.27B revenue and growth rates
  2. www.forbes.com — Market context about AI healthcare competitors and funding trends
  3. www.sec.gov — Industry benchmarks for AI-driven semiconductor testing growth
  4. www.sec.gov — Comparable AI-enhanced materials science business model